Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Karl Haslam, MPhil MBA, Niamh Appleby, FRCPath, Christopher Armstrong, MB MRCPI, Catherine M. Flynn, MD MRCP, FRCPath, Stephen Langabeer, PhD FRCPath, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2016) 128 (22): 2277.

https://doi.org/10.1182/blood.V128.22.2277.2277

Published: 2016

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Claire N. Harrison, Jean-Jacques Kiladjian, MD PhD, Florian H. Heidel, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, MD, Daniel B. Lipka, MD, Suddhasatta Acharyya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Susan Ide, PhD, Tracy Liu, Song Mu, PhD, Vincent Ribrag, MD

Blood (2015) 126 (23): 4060.

https://doi.org/10.1182/blood.V126.23.4060.4060

Published: 2015

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 711.

https://doi.org/10.1182/blood.V124.21.711.711

Published: 2014

Journal Articles

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Michael C O'Dwyer, MD, FRCPI, FRCPath, Emma Kent, Michael Parker, BSc, MSc, CStat, CMath, Ronan T. Swords, M.D., Frank Giles, MD, MB, FRCPI, FRCPath, Philipp le Coutre, MD, Swaminathan Padmanabhan, MD, MBBS, Brian Moulton, Ph.D, Mary Frances McMullin, Stephen Langabeer, PhD, Karine Egan, Ph.D, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2009) 114 (22): 3294.

https://doi.org/10.1182/blood.V114.22.3294.3294

Published: 2009

Journal Articles

Mutation Mediated Resistance to the Tyrosine Kinase Inhibitors Imatinib, Dasatinib & Nilotinib in Philadelphia Positive Leukaemia

Lisa M O’ Connor, PhD, Stephen Langabeer, PhD, Shaun R. McCann, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2008) 112 (11): 4245.

https://doi.org/10.1182/blood.V112.11.4245.4245

Published: 2008

NARROW

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Mutation Mediated Resistance to the Tyrosine Kinase Inhibitors Imatinib, Dasatinib & Nilotinib in Philadelphia Positive Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Mutation Mediated Resistance to the Tyrosine Kinase Inhibitors Imatinib, Dasatinib & Nilotinib in Philadelphia Positive Leukaemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only